Skip to main content
. Author manuscript; available in PMC: 2021 Sep 15.
Published in final edited form as: Clin Cancer Res. 2020 Dec 3;27(6):1766–1777. doi: 10.1158/1078-0432.CCR-20-1499

Figure 5. Survivin expression in human DIPG tumor tissue, patient-derived cell lines, and mouse xenograft tumors.

Figure 5.

A) Fold change in mRNA expression of the BIRC5 gene encoding the survivin protein in human DIPG tumor tissue samples, normalized to average expression across normal brain tissue from the same patients. B) Fold change in BIRC5 expression in human DIPG tumor tissue. ‘DIPG set 1’ data was acquired from the Children’s Brain Tumor Tissue Consortium (CBTTC) (n=14), and ‘DIPG set 2’ data was acquired from the Pediatric Brain Tumor Atlas (PNOC003) (n=31) dataset (PedcBioPortal). C) Immunohistochemistry of DIPG patient samples stained for survivin representing strong (score=III, patient 26), medium-strong (score=II, patient 14), weak (score=I, patient 77) and absent (score=0, patient number 27) expression (scale: 50μm). D) RNA expression of BIRC5 gene in normal human astrocytes (NHA) and patient-derived DIPG cell lines. E) qPCR analysis of basal BIRC5 mRNA expression in DIPG cell lines SF8628, SF7761, DIPG007. F) (i) Representative Western blot images and (ii) quantification of survivin protein expression normalized to actin expression in DIPG cell lines (One-way ANOVA with Tukey’s post hoc test, n=3. Levels of significance are: * p <0.05 and ** p <0.01).